Analyst firms · Stifel · TNDM

Stifel TNDM price target and rating history

Tandem Diabetes Care Inc. (TNDM) · Health Care

Stifel rates Tandem Diabetes Care Inc. (TNDM) Buy with a $26 price target, as of its latest action on Nov 18, 2026. It has published 3 rating actions on TNDM since March 2024, including 2 upgrades and 0 downgrades. Across 12 firms with a TNDM price target in the last 12 months, the median target is $26.50. Stifel's $26 is 2% below that.

Current rating
Buy
Price target
$26
Median target, all firms
$26.50
Actions on TNDM
3

Stifel price target on TNDM

$37$26$1520252026
Stifel price target on TNDM, each point a stated target, March 2024 to November 2026.

Every Stifel rating on TNDM

How other firms rate TNDM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
StifelBuy$26Nov 18, 2026
BarclaysEqual Weight$18Oct 7, 2026
CitigroupNeutral$20Sep 30, 2026
William BlairOutperformAug 21, 2026
UBSNeutral$18Jul 28, 2026
Deutsche BankHold$15.50Jun 23, 2026
Wells FargoOverweight$27Jun 1, 2026
The Benchmark CompanyHoldMay 12, 2026
Truist SecuritiesBuy$35Mar 19, 2026
Piper SandlerOverweight$33Mar 17, 2026
Lake StreetBuy$50Feb 23, 2026
BofA SecuritiesNeutral$30Feb 20, 2026
TD CowenBuy$25Jan 27, 2026
Robert W. BairdOutperform$30Dec 16, 2025

Questions about Stifel and TNDM

What is Stifel's price target for TNDM?
Stifel's latest stated price target for Tandem Diabetes Care Inc. (TNDM) is $26, from its action on Nov 18, 2026.
What is Stifel's rating on TNDM?
Stifel rates TNDM Buy, a bullish rating, as of Nov 18, 2026.
When did Stifel last change its view on TNDM?
On Nov 18, 2026, Stifel upgrades to Buy from Hold, price target $26.
How does Stifel's TNDM target compare with other analysts?
Across 12 firms with a TNDM price target in the last 12 months, the median target is $26.50. Stifel's $26 is 2% below that.

More TNDM rating histories

All Stifel ratingsTNDM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.